Clinical outcomes of persistent radioiodine uptake in the neck shown by diagnostic whole body scan in patients with differentiated thyroid carcinoma after initial surgery and remnant ablation

Clinical Endocrinology

Volumn 73, Issue 2, 2010, Pages 257-263

  Kim, Eui Young ^a   Kim, Won Gu ^a   Kim, Won Bae ^a   Kim, Tae Yong ^a   Ryu, Jin Sook ^a   Gong, Gyungyub ^a   Yoon, Jong Ho ^a   Hong, Suck Joon ^a   Lee, Jeong Hyun ^a   Baek, Jung Hwan ^a   Shong, Young Kee ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURGERY; CERVICAL LYMPH NODE; CHILD; DRUG UPTAKE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; SCHOOL CHILD; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; TREATMENT OUTCOME; TUMOR VOLUME; WHOLE BODY SCINTISCANNING;

ADOLESCENT; ADULT; AGED; CARCINOMA; CELL DIFFERENTIATION; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECK; NEOPLASM, RESIDUAL; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TREATMENT OUTCOME; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 77954872517     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03788.x     Document Type: Article

References (23)

1. Sherman, S.I. (2003) Thyroid carcinoma. Lancet, 361, 501 511.
2. Mazzaferri, E.L. Kloos, R.T. (2000) Using recombinant human TSH in the management of wel-differentiated thyroid cancer: current strategies and future directions. Thyroid, 10, 767 778.
3. Saghari, M., Gholamrezanezhad, A., Mirpour, S. et al. (2006) Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan. Nuclear Medicine Communications, 27, 567 572.
4. Mazzaferri, E.L., Robbins, R.J., Spencer, C.A. et al. (2003) A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 88, 1433 1441.
5. Pacini, F., Molinaro, E., Castagna, M.G. et al. (2003) Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 88, 3668 3673.
6. Ozata, M., Suzuki, S., Miyamoto, T. et al. (1994) Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 79, 98 105.
7. Luster, M., Clarke, S.E., Dietlein, M. et al. (2008) Guidelines for radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 35, 1941 1959.
8. Kim, T.Y., Kim, W.B., Kim, E.S. et al. (2005) Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 90, 1440 1445.
9. Lee, J.H., Lee, H.K., Lee, D.H. et al. (2007) Ultrasonographic findings of a newly detected nodule on the thyroid bed in postoperative patients for thyroid carcinoma: correlation with the results of ultrasonography-guided fine-needle aspiration biopsy. Clinical Imaging, 31, 109 113.
10. Ahn, J.E., Lee, J.H., Yi, J.S. et al. (2008) Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. World Journal of Surgery, 32, 1552 1558.
11. Pacini, F., Agate, L., Elisei, R. et al. (2001) Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. Journal of Clinical Endocrinology and Metabolism, 86, 4092 4097.
12. Pacini, F., Capezzone, M., Elisei, R. et al. (2002) Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. Journal of Clinical Endocrinology and Metabolism, 87, 1499 1501.
13. Ma, C., Kuang, A., Xie, J. et al. (2005) Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. Journal of Nuclear Medicine, 46, 1473 1480.
14. Brendel, A.J., Lambert, B., Guyot, M. et al. (1990) Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. European Journal of Nuclear Medicine, 16, 35 38.
15. Caballero-Calabuig, E., Cano-Terol, C., Sopena-Monforte, R. et al. (2008) Influence of the thyroid remnant in the elevation of the serum thyroglobulin after thyroidectomy in differentiated thyroid carcinoma. Importance of the diagnostic iodine total-body scanning. European Journal of Nuclear Medicine and Molecular Imaging, 35, 1449 1456.
16. Park, E.K., Chung, J.K., Lim, I.H. et al. (2009) Recurrentmetastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. European Journal of Nuclear Medicine and Molecular Imaging, 36, 172 179.
17. Batge, B., Dralle, H., Padberg, B. et al. (1992) Histology and immunocytochemistry of differentiated thyroid carcinomas do not predict radioiodine uptake: a clinicomorphological study of 62 recurrent or metastatic tumours. Virchows Archiv. A, Pathological Anatomy and Histopathology, 421, 521 526.
18. Hay, I.D. Klee, G.G. (1993) Thyroid cancer diagnosis and management. Clinics in Laboratory Medicine, 13, 725 734.
19. Hay, I.D., Thompson, G.B., Grant, C.S. et al. (2002) Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World Journal of Surgery, 26, 879 885.
20. Pace, L., Klain, M., Albanese, C. et al. (2006) Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. European Journal of Nuclear Medicine and Molecular Imaging, 33, 179 183.
21. Schlumberger, M.J. (1998) Papillary and follicular thyroid carcinoma. New England Journal of Medicine, 338, 297 306.
22. Utiger, R.D. (1997) Follow-up of patients with thyroid carcinoma. New England Journal of Medicine, 337, 928 930.
23. Sawka, A.M., Thephamongkhol, K., Brouwers, M. et al. (2004) Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 89, 3668 3676.